Clinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis, whatever the treatment-line: Results of the CATS retrospective registry.

Affiliation auteurs!!!! Error affiliation !!!!
TitreClinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis, whatever the treatment-line: Results of the CATS retrospective registry.
Type de publicationJournal Article
Year of Publication2019
AuteursDelanoy N, Hardy-Bessard A-C, Le Moulec S, Basso U, Birtle AJane, Thomson AH, Krainer M, De Giorgi U, Hasbini A, Daugaard KGedske, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard J-C, Flechon A, Thiery-Vuillemin A, Efstathiou E, Oudard S
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume37
Date PublishedMAR 1
Type of ArticleMeeting Abstract
ISSN0732-183X